Skip to content
Back to Investors
Scottish Enterprise

Scottish Enterprise

Government

Scottish Enterprise is a national economic development agency supporting business growth.


Recent investments

Other
£2.3M

The funding was led by The Conduit Impact Fund alongside participation from SIS Ventures, Equity Gap, Old College Capital and Scottish Enterprise.

"Our process is championing the circular economy and the investment we have secured will be transformational in helping MiAlgae scale quickly both locally and abroad."
— Douglas Martin, Managing Director
Other
£5.0M

The funding comprises private sector backing alongside a grant from Scottish Enterprise to advance maritime decarbonisation.

"Scotland’s decision to support this project shows that wind technology has the might of a maritime nation behind it. Shipping has a long history of harnessing the power of wind, but digital technologies are allowing us to work towards making zero emission vessels a reality. Smart Green Shipping’s FastRig wing sail technology offers a financially and technically robust solution to help support shipping’s green transition."
— Diane Gilpin, CEO and founder
Seed
£1.5M

The funding round was led by Archangels to support international expansion and product development.

"In a post-pandemic world, web-based clinical triage is becoming an increasingly an important part of how healthcare is delivered in the UK and globally, providing a vital service and reducing the burden on healthcare teams. I have no doubt that the clinical depth of the PhysioWizard product, which has been developed over many years, will ensure that it becomes the leading digital triage solution not only in the UK but globally."
— David Ovens, Joint MD
Seed
£1.6M

Archangels led the financing round to support the development of the company cell analysis platform.

"On behalf of our Board and employees I would like to thank our investors for their continued support of Cytomos. We now have the growth capital required to advance the development of our novel process analytical technology platform to the next phase of prototype evaluation with our strategic partners. This is an important milestone in the journey to deliver our mission to enable the development and manufacture of life saving biologic therapies"
— Alan Raymond, Executive Chairman